The DOI matches its Crossref record.
Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN)
Abstract
AIMS: To evaluate the safety and efficacy of levosimendan in patients with left ventricular failure complicating acute myocardial infarction. METHODS AND RESULTS: Levosimendan at different doses (0.1-0.4 microg x kg(-1) x min(-1)) or placebo were administered intravenously for 6h to 504 patients in a randomised, placebo-controlled, double-blind study. The primary end-point was hypotension or myocardial ischaemia of clinical significance adjudicated by an independent Safety Committee. Secondary end-points included risk of death and worsening heart failure, symptoms of heart failure and all-cause mortality. The incidence of ischaemia and/or hypotension was similar in all treatment groups (P=0.319). A higher frequency of ischaemia and/or hypotension was only seen in the highest levosimendan dose group. Levosimendan-treated patients experienced lower risk of death and worsening heart failure than patients receiving placebo, during both the 6h infusion (2.0% vs 5.9%; P=0.033) and over 24h (4.0% vs 8.8%; P=0.044). Mortality was lower with levosimendan compared with placebo at 14 days (11.7% vs 19.6%; hazard ratio 0.56 [95% CI 0.33-0.95];P =0.031) and the reduction was maintained at the 180-day retrospective follow-up (22.6% vs 31.4%; 0.67 [0.45-1.00],P =0.053). CONCLUSION: s Levosimendan at doses 0.1-0.2 microg x kg(-1) x min(-1) did not induce hypotension or ischaemia and reduced the risk of worsening heart failure and death in patients with left ventricular failure complicating acute myocardial infarction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Inotropes and Vasopressors: Review of Physiology and Clinical Use in Cardiovascular Disease
Overgaard, C. B., & Džavík, V. (2008) · Circulation · doi:10.1161/circulationaha.107.728840 · Cited by 516
Sympathetic Overstimulation During Critical Illness: Adverse Effects of Adrenergic Stress
Dünser, M. W., & Hasibeder, W. R. (2009) · Journal of Intensive Care Medicine · doi:10.1177/0885066609340519 · Cited by 488
Packer, M., Colucci, W., Fisher, L., Massie, B. M., Teerlink, J. R., Young, J., Padley, R. J., Thakkar, R., Delgado-Herrera, L., Salon, J., et al. (2013) · JACC: Heart Failure · doi:10.1016/j.jchf.2012.12.004 · Cited by 436
McMurray, J. J. V., Teerlink, J. R., Cotter, G., Bourge, R. C., Cleland, J. G. F., Jondeau, G., Krum, H., Metra, M., O’Connor, C. M., Parker, J. D., et al. (2007) · JAMA · doi:10.1001/jama.298.17.2009 · Cited by 360
Cleland, J. G. F., Freemantle, N., Coletta, A. P., & Clark, A. L. (2006) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2005.12.003 · Cited by 320
Metadata
- Authors
- Moiseyev, V
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2002-09-15
- Volume
- 23
- Issue
- 18
- Pages
- 1422-1432
- ISSN
- 0195-668X (ISSN-L)
- OpenAlex
- W2117483856
- Cited by
- 595
- References
- 0
- FWCI
- 23.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). https://app.cochat.ai/papers/10.1053/euhj.2001.3158
- The paper
- Moiseyev, V. (2002). Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). European Heart Journal. https://doi.org/10.1053/euhj.2001.3158
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.